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ABSTRACT 
Huntingtin protein (Htt) is ubiquitously expressed, yet Huntington’s disease (HD), a fatal 
neurologic disorder produced by expansion of an Htt polyglutamine tract, is 
characterized by neurodegeneration that occurs primarily in the striatum and cerebral 
cortex. Such discrepancies between sites of expression and pathology occur in multiple 
neurodegenerative disorders associated with expanded polyglutamine tracts. One 
possible reason is that disease-modifying factors are tissue-specific. Here we show that 
the striatum-enriched protein, CalDAG-GEFI, is severely down-regulated in the striatum 
of mouse HD models and is down-regulated in HD individuals. In the R6/2 transgenic 
mouse model of HD, striatal neurons with the largest aggregates of mutant Htt have the 
lowest levels of CalDAG-GEFI. In a brain-slice explant model of HD, knock-down of 
CalDAG-GEFI expression rescues striatal neurons from pathology induced by 
transfection of polyglutamine-expanded Htt exon 1. These findings suggest that the 
striking down-regulation of CalDAG-GEFI in HD could be a protective mechanism that 
mitigates Htt-induced degeneration.  
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INTRODUCTION 
The symptoms of HD include uncontrollable choreic movements and mood disturbances 
that progress until death, which typically occurs ten to twenty years after disease onset 
(1-2). There is an inverse correlation between the age of symptom onset and the length 
of a polyglutamine tract encoded by a CAG repeat within exon 1 of the IT15 gene (3-5). 
With disease progression, there is increasing loss of particular neuronal subtypes in the 
striatum and cerebral cortex of HD patients and, to a lesser degree, in other brain 
regions as well (6). It is unclear why, even within the severely affected striatum, subsets 
of neurons are differentially sensitive to mutant Htt. Transcriptional profiling studies of 
striatal and cortical postmortem tissue from HD patients and mouse models of HD have, 
however, identified candidate susceptibility factors as well as potentially protective, 
compensatory changes in gene expression (7-10).  
 One of the most significant transcriptional changes indicated by microarray studies 
of HD patients and animal models is the down-regulation of CalDAG-GEFI (a.k.a. 
RasGRP2) (7-9, 11). CalDAG-GEFI encodes a notably striatum-enriched cytoplasmic 
signaling molecule that has binding sites for calcium and diacylglycerol (DAG) and 
nucleotide exchange factor domains that target the small G proteins, Rap1 and Rap2 
(12-14). We have shown that signaling from CalDAG-GEFI to Rap-family GTPases in 
platelets and neutrophils is critical for integrin-dependent cell adhesion and vesicle 
release in vivo (13, 15-16). In the brain, we have shown that CalDAG-GEFI is 
predominantly expressed in medium spiny projection neurons of the striatum (12, 17) 
and in a subset of cortical neurons, cell types that are selectively destroyed in HD. 
CalDAG-GEFI is not expressed at high levels by striatal interneurons, which are 
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relatively spared in HD (18-19). Further, CalDAG-GEFI is differentially enriched in the 
matrix compartment of the striatum, relative to its levels in the striosomal compartment 
(12). This differential distribution is significant in light of evidence that, within the HD 
striatum, predominant neurodegeneration can occur in either one of these two striatal 
compartments (20-23) and is correlated with distinct symptom profiles (22).  
 Given this evidence, we examined CalDAG-GEFI protein expression in HD and HD 
mouse models and directly tested in an in vitro HD striatal assay whether CalDAG-GEFI 
expression could influence striatal pathology. We found that CalDAG-GEFI was down-
regulated in postmortem striatal samples from intermediate- and late-stage HD patients, 
as well as in the striatum of both the R6/1 and R6/2 mouse models of HD. In the R6/2 
mouse striatum, we tracked the timing of CalDAG-GEFI down-regulation and found it to 
correspond to the timing of disease progression. Unexpectedly, we found that the 
degree of down-regulation was strongly correlated with the size of the polyglutamine-
expanded Htt aggregates in striatal neurons. We therefore examined the possibility that 
reduced CalDAG-GEFI might mitigate cellular vulnerability to mutant Htt. We found that 
knock-down of CalDAG-GEFI expression protected striatal neurons from the severe 
pathology induced by polyglutamine-expanded Htt exon 1 in an organotypic striatal slice 
culture. These findings raise the clinically interesting possibility that reduced expression 
of CalDAG-GEFI in HD occurs as a neuroprotective mechanism to limit Htt-induced 
neuropathology. 
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RESULTS 
CalDAG-GEFI is down-regulated in Huntington’s Disease 
To test whether the expression of CalDAG-GEFI protein is disrupted in HD, we obtained 
postmortem tissue from the striatum of three patients with Huntington’s disease, one 
with intermediate-stage HD (Grade II-III) and two with late-stage HD (Grade IV) (6), and 
from sex-matched control brains that did not show striatal pathology. Western blot 
analysis showed that CalDAG-GEFI immunoreactivity was diminished in the striatal 
samples from all three HD brains, relative to those from the control brains (Fig. 1A). 
Based on comparison with a standard curve generated from 2X to 0.25X serial dilutions 
of the pooled control samples, this corresponded to 34 ± 12% (mean ± SEM) less 
CalDAG-GEFI protein in the HD striatum than in controls (Fig. 1A). These results 
confirm and extend the finding in microarray studies of severe down-regulation of 
CalDAG-GEFI mRNA in the striatum of HD patients (8-9). 
 To establish an experimental model for testing the effects of CalDAG-GEFI in HD, 
we next tested for the loss of CalDAG-GEFI in the most widely characterized mouse 
model of HD, the R6/2 line (24). R6/2 mice carry a transgene encoding the first exon of 
human IT15 with a CAG expansion of over 140 repeats. The onset of motor 
impairments occurs in these mice before 8 weeks of age, and their symptoms develop 
to include choreic and stereotypic movements, tremor and seizures that progress until 
death, at about 13 weeks of age (24). Severe shrinkage of brain neuropil occurs in the 
R6/2 mice, but cell death is minimal by comparison with that occurring in HD patients 
(24-25).  
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 In Western blots of brain tissue lysates from 12 week-old R6/2 mice, we found that 
CalDAG-GEFI immunoreactivity was reduced by 49% in the striatum (P < 0.02) and 
40% in neocortex (P < 0.03), relative to that measured in age-matched controls (Fig. 1B 
and C). By contrast, there was not a significant difference in the expression of CalDAG-
GEFI in hippocampal lysates from the two genotypes (P > 0.6; Fig. 1D), suggesting that 
the down-regulation of CalDAG-GEFI is limited to specific brain regions. We tracked the 
development of this deficit by harvesting brain tissue from R6/2 mice and littermate 
controls at 4, 8 and 12 weeks of age and examining the distribution of CalDAG-GEFI 
protein by immunohistochemistry (Fig. 1E). The immunoreactivity appeared slightly 
diminished in striatal brain sections from 4 week-old R6/2 mice (Fig. 1E), a time-point at 
which transcriptional changes are modest (10), but phenotypic abnormalities become 
apparent (10, 26-28). We observed progressive loss of CalDAG-GEFI immunostaining 
in 8 and 12 week-old R6/2 mice (Fig. 1E), ages at which increasingly severe motor 
complications occur (24). We also examined CalDAG-GEFI expression in symptomatic, 
9 month old R6/1 mice, which carry the same transgene as R6/2 mice, but which exhibit 
a slower disease progression as a result of reduced transgene expression (24). We 
observed severely diminished CalDAG-GEFI immunoreactivity in these late-stage mice 
as well (Fig. 1F). CalDAG-GEFI immunostaining was clearly matrix-predominant at each 
age in both the R6/1 and R6/2 mutants and the control mice (Fig. 1G and H). These 
findings demonstrate that, with disease progression and increasing severity of disease 
symptoms, CalDAG-GEFI expression is progressively lost in the striatum of R6/1 and 
R6/2 mice, as in the human HD striatum, and that the loss is selective for the matrix 
compartment of the striatum.  
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 To examine further the tissue-specificity of CalDAG-GEFI down-regulation, we 
measured CalDAG-GEFI expression and function in platelets from R6/2 mice. CalDAG-
GEFI is strongly expressed in platelets from normal mice and is critical for integrin-
dependent platelet adhesion and aggregation (13, 29). Western blots of platelet lysates 
from 12 week-old R6/2 mice and age-matched controls showed no significant 
differences in CalDAG-GEFI expression (Supplementary Material, Fig. S1A). 
Furthermore, we found that platelets from 12 week-old R6/2 mice undergo normal 
CalDAG-GEFI-mediated aggregation (Supplementary Material, Fig. S1B). Thus, the 
down-regulation of CalDAG-GEFI that occurs in striatum and cortex of R6/2 mice is not 
a generalized effect in all cells expressing CalDAG-GEFI. 
 
CalDAG-GEFI expression is inversely correlated with Htt aggregate size in R6/2 
model mice 
In R6/2 mice, we observed that a subset of striatal neurons maintained normal levels of 
CalDAG-GEFI immunoreactivity in their cell bodies, despite the overall down-regulation 
of striatal CalDAG-GEFI expression (Fig. 2A, right panel). These neurons appeared to 
be of the medium-sized neuronal phenotype that characterizes striatal projection 
neurons, which are normally enriched in CalDAG-GEFI (12, 17). Further, we found that 
these neurons co-expressed EGFP reporter genes that mark the expression of the 
striatum-enriched D1 and D2 dopamine receptors (Fig. 2B and C) (30). Thus, the 
scattered neurons with high levels of CalDAG-GEFI expression in the striatum of R6/2 
mice appeared to be dopaminoreceptive neurons that had not undergone down-
regulation of CalDAG-GEFI. Spurred by this observation, we examined the same brains 
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to determine which striatal neurons exhibited Htt protein aggregates, a neuropathologic 
hallmark of HD (31-32). Aggregates of mutant Htt are found in the nucleus and 
cytoplasm of neurons throughout the neocortex and, to a lesser degree, the striatum of 
patients with HD and R6/2 model mice (33-35). In accord with these findings, Htt-
positive neuronal intranuclear inclusions were abundant in the striatum and neocortex of 
the 12 week-old R6/2 mice (Fig. 2D, right panel). 
 We found a striking correspondence between the striatal neurons that maintained 
CalDAG-GEFI expression and the striatal neurons that lacked Htt-positive nuclear 
inclusions. Figure 2D shows the results of experiments in which we detected 
immunoreactivity for CalDAG-GEFI with antibodies conjugated to a red fluorophore and 
detected Htt with antibodies conjugated to a green fluorophore. CalDAG-GEFI did not 
colocalize with the intranuclear Htt inclusions (Fig. 2E), indicating that the loss of 
CalDAG-GEFI staining in the cytoplasm was not the result of sequestration in Htt 
inclusions. We applied deconvolution microscopy to obtain volumetric measurements of 
Htt-positive nuclear inclusions in striatal neurons that had high, intermediate or low 
levels of CalDAG-GEFI immunostaining. Striatal neurons with low levels of CalDAG-
GEFI had nuclear inclusions that were roughly three-fold larger than the nuclear 
inclusions in striatal neurons with high levels of CalDAG-GEFI immunostaining (Fig. 2F 
and G). This inverse correlation between Htt-positive inclusion volume and CalDAG-
GEFI expression was highly significant (P < 0.0001). 
  
Knock-down of CalDAG-GEFI expression is neuroprotective in a brain slice model 
of HD 
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To test whether changes in CalDAG-GEFI expression levels could influence the cellular 
pathology associated with HD, we performed CalDAG-GEFI over-expression and 
knock-down experiments in a rat organotypic cortico-striatal slice model of HD (36-38). 
A biolistic device was used to transfect these explants with exon 1 of human Htt bearing 
a polyglutamine expansion of 73 polyglutamines. In this system, the transfection of 
polyglutamine-expanded Htt exon 1 has been shown to induce progressive dendritic 
and cell body degeneration of medium spiny striatal neurons that can be visualized by 
co-transfection with yellow fluorescent protein (YFP; Fig. 3A-D) (36-38).  
 As in these previous studies, we observed that the number of healthy striatal 
neurons was reduced by ~2-fold in brain slices that were transfected with the mutant Htt 
construct, relative to the numbers found in the striatum of control slices transfected with 
YFP marker alone (Fig. 3E, P < 0.01). However, when we co-transfected cortico-striatal 
brain slices with the polyglutamine-expanded Htt exon 1 and with an siRNA that targets 
CalDAG-GEFI (15), the numbers of healthy striatal neurons were restored to control 
levels, relative to the numbers of healthy neurons in slices that were co-transfected with 
a control siRNA (Fig. 3E, P < 0.01). To ensure that the siRNA effectively knocked down 
rat CalDAG-GEFI, we transfected the rat striatal cell line ST14A with increasing 
concentrations of siRNA. We observed a dose-dependent reduction in CalDAG-GEFI 
protein expression, relative to cells transfected with a non-targeting control siRNA (Fig. 
3F). We also confirmed that the siRNA was effective in the explant system. We co-
transfected slices with YFP, siRNA and a CalDAG-GEFI-tdTomato fusion construct and 
then evaluated the tdTomato fluorescence intensity of medium spiny striatal cells that 
were co-tranfected with CalDAG-GEFI siRNA vs. control siRNA (Supplementary 
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Material, Fig. S2). In the slices that were co-transfected with CalDAG-GEFI siRNA, we 
found that there were significantly more cells classified as dim (P < 10-5), and 
significantly fewer cells classified as bright (P < 10-5), for expression of the CalDAG-
GEFI-tdTomato protein, relative to slices transfected with control siRNA. Thus, the 
siRNA targeting CalDAG-GEFI effectively knocked-down expression of the CalDAG-
GEFI-tdTomato fusion construct in the explant system. 
 As a control for the effects of CalDAG-GEFI knock-down alone, we repeated these 
experiments, transfecting the CalDAG-GEFI siRNA without co-transfection of the mutant 
Htt construct. There was no change in the numbers of healthy neurons relative to 
treatment with the control siRNA, demonstrating that the rescue effect of the CalDAG-
GEFI siRNA was specific to the presence of mutant Htt exon 1 (Fig. 3G). When we 
transfected YFP siRNA alone, the number of visible YFP-positive neurons visible was 
minimal, reflecting nearly complete knock-down of YFP protein expression and 
indicating that the siRNA transfection system itself was effective (Fig. 3G). Finally, we 
co-transfected slices with a CalDAG-GEFI over-expression construct together with the 
Htt construct and YFP. Whereas knock-down of CalDAG-GEFI rescued mutant Htt exon 
1-induced pathology in the slice system, over-expression of CalDAG-GEFI tended to 
exacerbate the toxic effects of mutant Htt on the striatal neurons (Fig. 3H, P = 0.05).  
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DISCUSSION 
Our findings suggest that the striatum-enriched signaling molecule, CalDAG-GEFI, may 
be functionally linked to neuronal degeneration in HD. CalDAG-GEFI protein levels were 
markedly decreased in the striatum of intermediate- and late-stage HD human brains 
examined and in the striatum of symptomatic R6/1 and R6/2 HD model mice. The down-
regulation appeared to be tissue-specific, given that CalDAG-GEFI expression was 
normal in the hippocampus and in platelets from R6/2 mice with end-stage disease. 
This tissue-selectivity of CalDAG-GEFI down-regulation stands in contrast to the 
regulation of numerous other genes that show parallel dysregulation in both brain and 
non-nervous system tissue in R6/2 mice, as tested in brain and muscle microarray 
assays (10).  
 Scattered cells within the striatum of R6/2 mice maintained high levels of CalDAG-
GEFI expression, and these cells had markedly smaller Htt-positive nuclear inclusions 
than did those with low CalDAG-GEFI expression. The CalDAG-GEFI-positive cells had 
the morphological appearance of medium-sized neurons and were dopaminoreceptive, 
judging from co-expression of EGFP BAC transgene reporters for either the Drd1a or 
the Drd2 dopamine receptors. These CalDAG-GEFI-enriched striatal neurons were 
presumed to be of the projection neuron phenotype, as CalDAG-GEFI mRNA is 
predominantly expressed in these neurons in wild-type animals (17) and CalDAG-GEFI 
protein is transported from the striatum to terminal sites in the pallidum and substantia 
nigra (12).  
 Such an inverse relationship is not the general rule for genes expressed in the 
striatum. It has been reported that there is no correlation between the presence of 
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aggregates and the down-regulation of at least three other striatum-enriched genes in 
the R6/2 mouse model (39).  
 The correlation between Htt-positive aggregate size and low CalDAG-GEFI 
expression demonstrated here raises as alternative possibilities that either 1) Htt 
aggregates, or correlated factors, inhibit CalDAG-GEFI expression, perhaps through the 
sequestration of transcription factors as recently shown for other striatum-enriched 
genes (11), or 2) CalDAG-GEFI blocks aggregate formation, perhaps through its 
downstream target, Rap2, which is implicated in aggresome formation (40-41) or 3) 
these processes work in combination. However, we did not observe obvious differences 
in the frequency of aggregates in striatal neurons in brain slice explants transfected with 
YFP and polyglutamine-expanded Htt exon 1 fused to cyan fluorescent protein (CFP) 
when CalDAG-GEFI expression was either knocked down or augmented 
(Supplementary Material, Fig. S3). Thus, our data indicate that the beneficial effects of 
CalDAG-GEFI knock-down in the explant assay are not related to aggregate formation. 
If this finding extends to striatal neurons in R6/2 mice, then aggregate formation might 
precede, and promote, CalDAG-GEFI down-regulation in this model. Together with our 
findings that CalDAG-GEFI is strongly down-regulated in the HD striatum, and that 
CalDAG-GEFI is lost gradually over time in the R6/2 striatum, our results suggest that in 
HD, striatal neurons increasingly down-regulate CalDAG-GEFI as cellular pathology 
progresses.  
  Our in vitro findings demonstrate that knock-down of CalDAG-GEFI expression, 
which mimics its down-regulation in HD and HD models, rescues striatal neurons from 
the neuropathology induced by polyglutamine-expanded Htt exon 1 (36-38). 
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Conversely, over-expression of CalDAG-GEFI in the brain slice model exacerbated the 
neuronal pathology associated with expression of polyglutamine-expanded Htt in this 
assay. Whereas knock-down of CalDAG-GEFI provided complete rescue from the 
pathology that was measured in this assay system, overexpression of CalDAG-GEFI 
had only a modest effect. This contrast likely reflects the fact that basal levels of 
CalDAG-GEFI are already so high in striatal neurons that overexpression has relatively 
little effect on CalDAG-GEFI signaling pathways. Nevertheless, this set of results 
concordantly support the hypothesis that down-regulation of CalDAG-GEFI is 
neuroprotective against neurodegenerative processes induced by polyglutamine-
expanded Htt exon 1.  
 The mechanisms that might underlie this effect are as yet unclear, but they could 
involve elimination of toxic conformations of Htt or down-regulation of calcium-induced 
cytotoxic signaling. The calcium binding motifs in CalDAG-GEFI suggest that the protein 
might be highly sensitive to excitotoxic signaling, suggested to occur in HD (42-43). 
Experimentally-induced strong excitation of the neocortex elevates intracellular calcium 
and activates the extracellular-regulated kinases, ERK1/2, in striatal neurons (44-46). In 
heterologous cell culture systems, CalDAG-GEFI regulates ERK (12, 47). These 
findings raise the possibility that compensatory down-regulation of CalDAG-GEFI might 
influence ERK signaling in the HD models. However, the role of ERK1/2 activation in the 
pathogenesis of HD remains unclear. Activated ERK1/2 levels are elevated in the 
striatum of R6/2 mice, despite an apparent reduction in downstream ERK1/2 signaling 
(48). In cell culture, it has been shown that potentiation of the ERK1/2 signaling cascade 
diminishes cell-death caused by expanded Htt expression (44, 49). ERK1/2 signaling is 
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also implicated in another hyperkinetic movement condition, L-DOPA-induced 
dyskinesia. ERK1/2 activity is elevated in models of L-DOPA-induced dyskinesia and 
blockade of this activity alleviates the abnormal movements. We previously have found, 
in a rat model of L-DOPA-induced dyskinesia, that the matrix-enriched CalDAG-GEFI is 
down-regulated, whereas the striosome-enriched paralog, CalDAG-GEFII, is 
upregulated (50). We suggested that the opposing dysregulation of these two ERK1/2 
regulators could contribute to the imbalance in striosome:matrix activity observed in 
models of L-DOPA-induced dyskinesia. Similarly, the down-regulation of CalDAG-GEFI 
in HD would be expected to have compartment-specific effects. However, to our 
knowledge, the dysregulation of ERK1/2 activity in relation to these compartments has 
not been examined in HD models. What is known is that either the striosome or the 
matrix compartment can be differentially affected in HD brains examined post-mortem, 
suggesting that compartmentalized gene expression is likely to be important in the 
etiology or expression of the disorder.  
 The working hypothesis prompted by these findings is that as the expression of 
CalDAG-GEFI falls in HD, a neuroprotective effect of CalDAG-GEFI down-regulation, 
possibly through ERK1/2 regulation and/or calcium signaling, would thus increase. 
Several other calcium-responsive signal transduction molecules are down-regulated in 
HD (51), but whether their down-regulation is neuroprotective has not been 
demonstrated.  
 Our findings extend evidence that changes in calcium-related signaling could be 
significant in HD (43), and further suggest that the effects of this signaling could have an 
impact on CalDAG-GEFI-dependent mechanisms such as cell adhesion, vesicle release 
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and Ras/Rap/ERK signaling in the striatum. As CalDAG-GEFI is normally expressed 
predominantly in projection neurons in the matrix compartment of the striatum, aberrant 
calcium signaling in matrix-based pathways could be a major feature of the disease 
process even before massive loss of tissue. In the brains of HD patients studied 
postmortem, both matrix-predominant patterns of cell loss and striosome-predominant 
patterns of cell loss have been observed, with each being correlated to individual 
symptom profiles (20-23). Our findings suggest that CalDAG-GEFI-related signaling 
pathways could contribute to these differential pathologies by virtue of their predominant 
expression in the matrix compartment, particularly related to sensory-motor functions of 
the striatum and cortico-basal ganglia pathways.  
 Within the striatum, the striatal interneurons that express low levels of CalDAG-GEFI 
are initially spared in HD, relative to the severe neurodegeneration that occurs in the 
CalDAG-GEFI-enriched projection neurons. Along with neurodegeneration of the 
striatum, select areas of the neocortex undergo thinning in the earliest, pre-symptomatic 
stages of HD (52-53); although CalDAG-GEFI is expressed in subsets of cortical 
neurons in rodents (17), we have not determined whether these cell types correspond to 
the complex pattern of cortical degeneration observed in human HD. Nevertheless, the 
pattern of relative loss in the striatum could indicate that high levels of cytoplasmic 
CalDAG-GEFI are correlated with selective vulnerability to Htt-induced toxicity. This 
possibility is supported by our observation that CalDAG-GEFI over-expression in 
organotypic brain slices exacerbates the degeneration of striatal neurons transfected 
with polyglutamine-expanded Htt exon 1. Critically, co-transfection with an siRNA 
knock-down construct for CalDAG-GEFI rescued neuronal pathology in the brain slice 
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model. Thus, our findings are consistent with the hypothesis that the expression of 
CalDAG-GEFI in medium spiny striatal neurons and in a subset of cortical neurons 
confers differential vulnerability of these cell types to neuropathology associated with 
mutant Htt.  
 CalDAG-GEFI is one of the most heavily down-regulated transcripts identified in 
microarray screens for transcriptome changes in HD and models of HD (7-9, 11). Our 
findings raise the possibility that this down-regulation could represent an endogenous, 
homeostatic mechanism countering neuronal dysfunction in the striatum in HD. If so, 
early regulation of CalDAG-GEFI expression could represent a novel therapeutic 
strategy for early intervention.  
 
MATERIALS AND METHODS  
 
Animal husbandry 
Mice and rats were maintained under a standard light/dark cycle with free access to 
food and water. Procedures for the mouse studies were in strict accordance with the 
MIT Committee on Animal Care, accredited by AAALAC (USA), and with Home Office 
(UK) regulations. All procedures used for the rats were in strict accordance with Duke 
Institutional Animal Care and Use Committee guidelines.  
 
Mouse brain immunolabeling 
Brains were obtained from R6/1 and R6/2 female mice and age-matched controls 
(generated by breeding R6/1 or R6/2 males to [CBA/Ca x C57BL/6/J] F1 females 
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[B6CBAF1/OlaHsd, Harlan Olac, Bichester, UK]) from the laboratory of Dr. Gillian 
Bates. Mice were deeply anesthetized prior to transcardial perfusion with buffered 4% 
paraformaldehyde. Brains were stored and shipped to MIT in a cryoprotectant buffer, 
and 24 m-thick frozen transverse sections through the striatum were cut on a sliding 
microtome. Sections were processed for immunohistochemistry with rabbit polyclonal 
anti-CalDAG-GEFI antiserum #3752 (13) and anti-rabbit antibody coupled to biotin for 
ABC amplification (Vector Laboratories). Sections from the R6/2 and R6/1 and control 
mice were processed in parallel by an individual blinded to genotype.  
 Brain sections from R6/2 mice that carried a Drd1a-EGFP or Drd2-EGFP BAC 
transgene were processed for immunofluorescence with anti-CalDAG-GEFI antiserum 
#3752 plus anti-EGFP antiserum (Abcam). Sections were subsequently incubated with 
anti-rabbit coupled to ALEXA594 antiserum plus anti-goat coupled to ALEXA488 
antiserum (Invitrogen Corp.). Sections were mounted and coverslipped with Vectashield 
media (Vector Laboratories) and imaged on an Olympus BX61 fluorescent microscope 
with an Olympus DP70 digital camera. 
 
Human tissue isolation 
Frozen brain tissue was provided by the Neuropathology Core of the Massachusetts 
Alzheimer Disease Research Center and was prepared as described by Vonsattel and 
coworkers (54). The control samples were from 45, 82 and 92 year old males with no 
remarkable brain pathology, the HD case samples were from 48, 59 and 72 year old 
males who were judged to have moderate to severe degeneration of the striatum and 
scattered ubiquitin-positive intranuclear inclusions.  




To prepare striatal tissue from mice, brains were removed from deeply anesthetized 
R6/2 male mice and age-matched sibling controls and striatal tissue was immediately 
dissected and frozen. Platelets were isolated by collecting blood into serum-separation 
tubes, spinning serum for 10 min at 3,000 X g and freezing platelet pellets on dry ice. 
Samples from the human caudate nucleus and putamen were dissected from frozen 
sections. Tissue was homogenized in ice-cold modified RIPA buffer (50 mM Tris pH 8.0, 
150 mM NaCl, 1% Triton X-100, 0.1% sodium dodecyl sulfate, 1% NaDeoxycholate) 
with Complete protease inhibitor cocktail (Roche) and was centrifuged at 16,000 X g for 
10 min to remove insoluble material. Supernatants were analyzed by bicinchoninic acid 
assays (Thermo Fisher Scientific) to determine total protein concentration. Protein (40 
g lysate per lane) was resolved by SDS-PAGE and transferred to PVDF membrane 
(Millipore) by electroblotting. Blots were incubated with anti-CalDAG-GEFI rabbit 
polyclonal antiserum #3752 (13) and anti-rabbit antibody coupled to horseradish 
peroxidase prior to immunodetection with Western Lightening (PerkinElmer Inc.) 
according to the manufacturer’s instructions. Blots were subsequently incubated with 
anti-β-tubulin (Cell Signaling Technology) or anti-Tuj1 (Abcam Inc.) antibodies to control 
for protein loading. Blots were scanned (UMAX), and the pixel density and size of the 
immunoreactive bands was calculated with ImageJ (NIH). To normalize for background 
signal and protein loading, the mean pixel density of an equivalently-sized area below 
the immunoreactive band was subtracted from each band and the result was divided by 
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the mean pixel density of the normalized Tuj1 band. Normalized intensity results were 
averaged within genotypes for comparison.  
 
Deconvolution microscopy  
Sections through the striatum were processed as described above for 
immunohistochemistry except that sections were double-labeled by simultaneous 
incubation with rabbit anti-CalDAG-GEFI and mouse monoclonal EM48 anti-Htt 
antibodies (MAB5374; Chemicon International) followed by fluorescent secondary 
antibodies (anti-mouse coupled to ALEXA 488 and anti-rabbit coupled to ALEXA 564; 
Invitrogen Corp.). Sections were mounted and coverslipped with Vectashield media 
(Vector Laboratories). 
 A 100X objective on a Zeiss Axioplan 2 microscope fitted with a Hamamatsu ORCA-
ER digital camera was used to obtain images from the medial striatum in two sections 
each from the brains of three R6/2 female mice (12 week-old). Striatal neurons were 
rated as having high, medium or low levels of anti-CalDAG-GEFI immunofluorescence 
by observation through the red channel alone to prevent biased cell-selection based on 
inclusion size (visible only through the green channel). Subsequently, a Z-stack of 
images through each neuron (Z step = 0.5 m) was acquired on the green channel, 
using Openlab Improvision software. Automatic exposure normalization was followed to 
control for variable staining intensity among the sections. Z-series data were 
deconvolved using Volocity Improvision software, and volume measurements of the 
MAB5374-immunoreactive inclusions were calculated by Volocity.  
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Transfection of ST14A cells  
To test siRNA efficiency, ST14A cells were grown in Dulbecco’s Modified Eagle’s media 
and fetal calf serum to 50% confluency in a 48-well tissue culture dish and transfected 
with CalDAG-GEFI or non-targeting siRNA (Integrated DNA Technologies) with 
Lipofectamine 2000 (Invitrogen) following manufacturer’s instructions. Forty-eight hours 
later, cells were lysed in RIPA buffer with Complete protease inhibitor cocktail (Roche) 
in preparation for CalDAG-GEFI immunoblotting, 
 
Cortico-striatal organotypic brain slice assay  
Cortico-striatal brain slices (250 µm-thick) from Sprague-Dawley rat pups (Charles 
River, postnatal day 10) were cut on a vibratome. The slices were maintained in 
interface cultures with culture medium containing 15% heat-inactivated horse serum, 10 
mM KCl, 10 mM HEPES, 100 U/ml penicillin/streptomycin, 1 mM MEM sodium 
pyruvate, and 1 mM L-glutamine in Neurobasal A (Invitrogen) under 5% CO2 at 32°C. A 
biolistic device (Helios Gene Gun; Bio-Rad) was then used to transfect brain slices with 
1.6 μm gold particles (BioRad) that can bind plasmid DNAs as previously described 
(55), or with surface-modified gold particles (Seashell Technology) capable of binding 
both plasmid DNA and siRNAs. The Htt expression plasmid used contained human IT15 
exon 1 with a 73 polyglutamine repeat subcloned into the gWIZ expression vector 
(Gene Therapy Systems, Inc.) and was constructed based on clones and sequences 
that were generous gifts of Dr. Christopher Ross (Johns Hopkins University) and the 
Hereditary Disease Foundation. The CalDAG-GEFI over-expression construct consisted 
of a full-length mouse CalDAG-GEFI cDNA subcloned into a separate gWIZ expression 
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plasmid. The CalDAG-GEFI-tdTomato fusion construct was generated by cloning 
mouse CalDAG-GEFI cDNA into the 3’ end of the Living Colors tdTomato vector 
(Clontech). The siRNA against CalDAG-GEFI was generated by Integrated DNA 
Technologies with the targeting sequence 5'-AAAGCGCAAGATGTCCCTGTT-3' (15). 
Brain slices were co-transfected with a YFP expression construct in all cases so that 
medium spiny neurons could be imaged and identified by their location within the 
striatum and by their characteristic dendritic arborization. Medium spiny neurons 
exhibiting normal cell body diameters, even and continuous expression of YFP within all 
cell compartments, and more than two discernable primary dendrites with each more 
than two cell body-diameters long were scored as "healthy" (see Figure 3A).  
 For estimation of aggregate frequencies, a similar Htt exon 1 construct was used 
with the same 73 polyglutamine repeat but also included a C-terminal fusion with cyan 
fluorescent protein to allow direct visualization of aggregate formation. For these 
experiments, brain slices were fixed 24 hours after biolistic transfection in order to 
capture the initial phases of aggregate formation; fixation was done using 2.5% 
paraformaldehyde, 0.5% glutaraldehyde, and 4% sucrose in PBS. After 30 minutes, 
slices were washed extensively with PBS and mounted in Vectashield (Vector Labs). 




Supplementary Material is available at HMG online. 
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Legends to Figures 
 
Figure 1. CalDAG-GEFI is down-regulated in Huntington’s disease. (A) Western 
blot of lysates from the striatum illustrating reduced CalDAG-GEFI immunoreactivity in 
three individuals with Huntington’s disease (HD), relative to three control individuals. 
HD1 and HD2 samples were from cases with Grade IV HD and HD3 sample was from 
an indiviidual with Grade II-III HD. Striatal lysates from wildtype (WT) and CalDAG-GEFI 
knockout (KO) mice were processed in parallel to demonstrate antibody specificity 
(right-most two lanes of lower blot). The relative immunoreactivity in HD vs. control 
samples (bar graph) was calculated from a standard curve generated by serial dilution 
of the pooled control samples in the blot shown at top. Anti-Tuj1 bands show controls 
for protein loading. Data are representative of those in three experiments. (B-D) 
Western blot of lysates from striatum (B), neocortex (C) and hippocampus (D) from 
three 12 week old R6/2 mice with polyglutamine repeat lengths between 192 and 194, 
compared to blots from age-matched sibling controls. Reduced CalDAG-GEFI 
immunoreactivity is apparent in striatum and neocortex, but not hippocampus, of R6/2 
mice. Anti-Tuj1 bands are shown as controls for protein loading. Bar graphs of average 
normalized immunoreactivity for controls and R6/2 samples are shown to the right of 
each blot; *P < 0.05. (E) Transverse sections from the brains of R6/2 (polyglutamine 
repeat lengths between 197 and 204) and control mice immunostained for CalDAG-
GEFI. CalDAG-GEFI immunostaining, relative to that in controls, gradually diminished 
with increasing age (4, 8 and 12 weeks of age). The 12 week old R6/2 mice exhibited 
severe depletion of CalDAG-GEFI, especially medially. Images are representative of 
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immunostaining observed in 4 individual R6/2 mice of each age, compared to 4 age-
matched controls. Scale bar, 1 mm. (F) Transverse sections from the brains of 
symptomatic R6/1 and control mice demonstrating down-regulation of CalDAG-GEFI 
immunostaining. (G, H) High-magnification photomicrographs illustrating CalDAG-GEFI 
immunostained matrix tissue surrounding a striosome (dotted outline). Scale bar, 0.1 
mm. (G) A 12 week-old control (left) and R6/2 mutant (right). (H) A 9 month-old control 
(left) and R6/1 mutant (right). 
 
Figure 2. CalDAG-GEFI down-regulation is correlated with Htt aggregate size in 
striatal neurons of R6/2 mice. (A) Immunostaining for CalDAG-GEFI in medium-sized 
neurons (examples at arrows) in the striatum of control (left) and 12 week-old R6/2 
mutant (right), illustrating abundant CalDAG-GEFI-positive medium-sized neurons in 
control striatum and sharply diminished numbers of CalDAG-GEFI-positive neurons in 
R6/2 striatum. Scale bar indicates 100 µm. Inset on right shows magnified image of the 
CalDAG-GEFI immunostained neuron indicated by an arrow in R6/2 striatum. Scale bar, 
50 µm. (B, C) Immunofluorescence for EGFP (green, left panels) and CalDAG-GEFI 
(red, middle panels) in 12 week-old R6/2 mice that carried a BAC transgene for the D1 
dopamine receptor (B) or the D2 dopamine receptor (C). Arrows indicate cells with high 
levels of CalDAG-GEFI and co-expression of EGFP. Scale bars indicate 50 µm. (D) 
Double immunofluorescence for CalDAG-GEFI (red) and Htt (green) in the dorsolateral 
striatum and overlying neocortex of control (left) and R6/2 (right) mice. Neurons that 
retained CalDAG-GEFI expression in R6/2 mice exhibited reduced incidence and/or 
size of Htt-positive nuclear inclusions (green). Scale bar, 100 µm. (E) No colocalization 
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of CalDAG-GEFI and Htt was observed, as demonstrated by single-channel imaging of 
CalDAG-GEFI immunoreactivity in the cell soma (left) and Htt immunoreactivity in a 
neighboring aggregate (right) of the the neuron indicated in D. Scale bar, 50 µm. (F) 
Estimated inclusion size in 143 striatal neurons from 12 week-old R6/2 mice. Samples 
included 50 cells with low, 34 cells with intermediate and 59 cells with high CalDAG-
GEFI immunostaining. Inclusion size and immunodetectable CalDAG-GEFI levels were 
inversely related (P < 0.0001 by Kendall correlation test). All groups were significantly 
different (P < 0.01 by Tukey’s post-hoc comparison) following one-way ANOVA (F(2, 
144) = 91.15, P < 0.0001). Bars show means ± SEM. (G) Size distribution of all 
inclusions that were included in the bar graph in F. 
 
Figure 3. CalDAG-GEFI knock-down rescues neuropathology induced by 
polyglutamine-expanded Htt exon 1 in cortico-striatal brain slice explants. (A-D) 
Visual assessment of healthy versus unhealthy medium spiny striatal neurons in striatal 
organotypic brain slices. (A) A YFP-transfected striatal neuron, illustrating YFP-positive 
dendrites and a rounded cell body. (B-D) Examples of neurons with increasing degrees 
of dendritic dystrophy and loss, from slices co-transfected with polyglutamine-expanded 
Htt exon 1 and YFP. Scale bar, 50 µm. (E) Slices co-transfected with polyglutamine-
expanded Htt exon 1 and YFP (light blue bars) showed about half the number of healthy 
striatal neurons found in slices transfected with YFP alone (dark blue bars). 
Transfection with a siRNA against CalDAG-GEFI rescued neuronal health of neurons 
co-transfected with mutant Htt exon 1 (pink bars). Data are shown for three independent 
experiments, with 5-20 brain slices for each bar, with corresponding SEMs. *P < 0.01 for 
within experiment comparisons of all three conditions by Dunnett's post hoc 
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comparison, following one-way ANOVA. (F) Western blots of lysates from ST14A rat 
striatal cells showed that transfection with CalDAG-GEFI siRNA dose-dependently 
knocks-down CalDAG-GEFI expression. Anti-Tuj1 bands show controls for protein 
loading. (G) Transfection of CalDAG-GEFI siRNA without concomitant transfection of 
mutant Htt does not increase numbers of healthy striatal neurons, relative to those in 
slices treated with control siRNA. YFP siRNA co-transfection leads to almost complete 
loss of YFP-positive neurons, demonstrating the efficiency of siRNA transfection. (H) 
Cortico-striatal brain slices co-transfected with mutant Htt exon 1 and a CalDAG-GEFI 
cDNA construct showed further decreases in numbers of healthy striatal neurons (red 
bars), relative to transfection with polyglutamine-expanded Htt exon 1. The decreases 
appeared proportional to the amount of CalDAG-GEFI cDNA loaded (1:1 vs. 3:1 
CalDAG-GEFI:YFP DNA by mass). For the 3:1 condition, *P = 0.05 by Dunnett's post 
hoc comparison following ANOVA. Data shown were pooled from n = 11-12 brain slices 
for each bar; means ± SEM are shown. Data are representative of two independent 
experiments.  




Figure 1. CalDAG-GEFI is down-regulated in Huntington’s disease. (A) Western blot of lysates from the striatum illustrating 
reduced CalDAG-GEFI immunoreactivity in three individuals with Huntington’s disease (HD), relative to three control individuals. 
HD1 and HD2 samples were from cases with Grade IV HD and HD3 sample was from an indiviidual with Grade II-III HD. Striatal 
lysates from wildtype (WT) and CalDAG-GEFI knockout (KO) mice were processed in parallel to demonstrate antibody specificity 
(right-most two lanes of lower blot). The relative immunoreactivity in HD vs. control samples (bar graph) was calculated from a 
standard curve generated by serial dilution of the pooled control samples in the blot shown at top. Anti-Tuj1 bands show controls for 
protein loading. Data are representative of those in three experiments. (B-D) Western blot of lysates from striatum (B), neocortex 
(C) and hippocampus (D) from three 12 week old R6/2 mice with polyglutamine repeat lengths between 192 and 194, compared to 
blots from age-matched sibling controls. Reduced CalDAG-GEFI immunoreactivity is apparent in striatum and neocortex, but not 
hippocampus, of R6/2 mice. Anti-Tuj1 bands are shown as controls for protein loading. Bar graphs of average normalized 
immunoreactivity for controls and R6/2 samples are shown to the right of each blot; *P < 0.05. (E) Transverse sections from the 
brains of R6/2 (polyglutamine repeat lengths between 197 and 204) and control mice immunostained for CalDAG-GEFI. CalDAG-
GEFI immunostaining, relative to that in controls, gradually diminished with increasing age (4, 8 and 12 weeks of age). The 12 week 
old R6/2 mice exhibited severe depletion of CalDAG-GEFI, especially medially. Images are representative of immunostaining 
observed in 4 individual R6/2 mice of each age, compared to 4 age-matched controls. Scale bar, 1 mm. (F) Transverse sections 
from the brains of symptomatic R6/1 and control mice demonstrating down-regulation of CalDAG-GEFI immunostaining. (G, H) 
High-magnification photomicrographs illustrating CalDAG-GEFI immunostained matrix tissue surrounding a striosome (dotted 
outline). Scale bar, 0.1 mm. (G) A 12 week-old control (left) and R6/2 mutant (right). (H) A 9 month-old control (left) and R6/1 mutant 
(right). 















Figure 2. CalDAG-GEFI down-regulation is correlated with Htt aggregate size in striatal neurons of R6/2 mice. (A) 
Immunostaining for CalDAG-GEFI in medium-sized neurons (examples at arrows) in the striatum of control (left) and 12 week-old 
R6/2 mutant (right), illustrating abundant CalDAG-GEFI-positive medium-sized neurons in control striatum and sharply diminished 
numbers of CalDAG-GEFI-positive neurons in R6/2 striatum. Scale bar indicates 100 µm. Inset on right shows magnified image of 
the CalDAG-GEFI immunostained neuron indicated by an arrow in R6/2 striatum. Scale bar, 50 µm. (B, C) Immunofluorescence for 
EGFP (green, left panels) and CalDAG-GEFI (red, middle panels) in 12 week-old R6/2 mice that carried a BAC transgene for the D1 
dopamine receptor (B) or the D2 dopamine receptor (C). Arrows indicate cells with high levels of CalDAG-GEFI and co-expression 
of EGFP. Scale bars indicate 50 µm. (D) Double immunofluorescence for CalDAG-GEFI (red) and Htt (green) in the dorsolateral 
striatum and overlying neocortex of control (left) and R6/2 (right) mice. Neurons that retained CalDAG-GEFI expression in R6/2 mice 
exhibited reduced incidence and/or size of Htt-positive nuclear inclusions (green). Scale bar, 100 µm. (E) No colocalization of 
CalDAG-GEFI and Htt was observed, as demonstrated by single-channel imaging of CalDAG-GEFI immunoreactivity in the cell 
soma (left) and Htt immunoreactivity in a neighboring aggregate (right) of the the neuron indicated in D. Scale bar, 50 µm. (F) 
Estimated inclusion size in 143 striatal neurons from 12 week-old R6/2 mice. Samples included 50 cells with low, 34 cells with 
intermediate and 59 cells with high CalDAG-GEFI immunostaining. Inclusion size and immunodetectable CalDAG-GEFI levels were 
inversely related (P < 0.0001 by Kendall correlation test). All groups were significantly different (P < 0.01 by Tukey’s post-hoc 
comparison) following one-way ANOVA (F(2, 144) = 91.15, P < 0.0001). Bars show means ± SEM. (G) Size distribution of all 
inclusions that were included in the bar graph in F. 







Figure 3. CalDAG-GEFI knock-down rescues neuropathology induced by polyglutamine-expanded Htt exon 1 in cortico-
striatal brain slice explants. (A-D) Visual assessment of healthy versus unhealthy medium spiny striatal neurons in striatal 
organotypic brain slices. (A) A YFP-transfected striatal neuron, illustrating YFP-positive dendrites and a rounded cell body. (B-D) 
Examples of neurons with increasing degrees of dendritic dystrophy and loss, from slices co-transfected with polyglutamine-
expanded Htt exon 1 and YFP. Scale bar, 50 µm. (E) Slices co-transfected with polyglutamine-expanded Htt exon 1 and YFP (light 
blue bars) showed about half the number of healthy striatal neurons found in slices transfected with YFP alone (dark blue bars). 
Transfection with a siRNA against CalDAG-GEFI rescued neuronal health of neurons co-transfected with mutant Htt exon 1 (pink 
bars). Data are shown for three independent experiments, with 5-20 brain slices for each bar, with corresponding SEMs. *P < 0.01 
for within experiment comparisons of all three conditions by Dunnett's post hoc comparison, following one-way ANOVA. (F) Western 
blots of lysates from ST14A rat striatal cells showed that transfection with CalDAG-GEFI siRNA dose-dependently knocks-down 
CalDAG-GEFI expression. Anti-Tuj1 bands show controls for protein loading. (G) Transfection of CalDAG-GEFI siRNA without 
concomitant transfection of mutant Htt does not increase numbers of healthy striatal neurons, relative to those in slices treated with 
control siRNA. YFP siRNA co-transfection leads to almost complete loss of YFP-positive neurons, demonstrating the efficiency of 
siRNA transfection. (H) Cortico-striatal brain slices co-transfected with mutant Htt exon 1 and a CalDAG-GEFI cDNA construct 
showed further decreases in numbers of healthy striatal neurons (red bars), relative to transfection with polyglutamine-expanded Htt 
exon 1. The decreases appeared proportional to the amount of CalDAG-GEFI cDNA loaded (1:1 vs. 3:1 CalDAG-GEFI:YFP DNA by 
mass). For the 3:1 condition, *P = 0.05 by Dunnett's post hoc comparison following ANOVA. Data shown were pooled from n = 11-
12 brain slices for each bar; means ± SEM are shown. Data are representative of two independent experiments.  
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